NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds
Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares, approved at the Extraordinary General Meeting on January 17, 2019 ("Rights Issue"). The Rights Issue has been subscribed to approximately MSEK 74.5, corresponding to a subscription ratio of approximately 60.2 percent, which means that approximately 19.8 percent of the total volume of the Rights Issue was allocated to guarantors. Through the Rights Issue, NeuroVive will thus raise approximately